EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Siglec-9 acts as an immune checkpoint marker on MDSCs in brucella infection

Huidong Shi, Xinxin Qi, Kaiyu Shang, Tingting Tian, Jianbing Ding, Mingzhe Li, Ruixue Xu, Fuling Pu, Junyu Kuang, Yuejie Zhu, Fengbo Zhang

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1652116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Huidong Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang …. Hauptthemen laut MEDLINE: Brucellosis, Myeloid-Derived Suppressor Cells, Sialic Acid Binding Immunoglobulin-like Lectins, Immune Checkpoint Proteins. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brucellosis is a zoonotic disease that is widely prevalent in the Xinjiang region of China. Once it progresses to a chronic stage, it can lead to significant complications. Immune checkpoints markers on Myeloid-derived suppressor cells (MDSCs) may lead to the chronic stage of the disease. This study analyzed the changes in MDSCs, immune checkpoints markers and cytokines in the patients with acute and chronic Brucella infections and after antibiotic treatment, to explore their roles and provide new ideas for future clinical treatment.

Methods

A total of 37 patients with acute brucellosis infection (ABI) and 46 patients with chronic brucellosis infection (CBI) and 43 healthy controls (HC) subjects were enrolled. Flow cytometry was used to detect the expression of MDSCs, Siglec-9 + MDSCs, PD-1 + MDSCs and Tim-3 + MDSCs before and after antibiotic treatment. In addition, ELISA was used to measure the levels of cytokines and the changes in IL-6 and Arg-1 of them were assessed again after antibiotic treatment.

Results

Our study found that the levels of MDSCs in the patients significantly increased, with CBI patients exhibiting higher levels than ABI patients. The cytokines showed varying degrees of elevation. Furthermore, after antibiotic treatment, the levels of MDSCs, Siglec-9 + MDSCs, PD-1 + MDSCs and Tim-3 + MDSCs in effective treatment patients significantly decreased. In contrast, the levels of MDSCs in ineffective treatment patients increased, while there were no significant differences in PD-1 + MDSCs and Tim-3 + MDSCs levels compared to before treatment. Notably, the levels of Siglec-9 + MDSCs in ineffective treatment showed a significant increase. In the ineffective treatment patients, the serum levels of Arg-1 and IL-6 both increased compared to before treatment. Correlation analysis revealed a positive correlation in ineffective treatment patients between serum Arg-1 levels and MDSCs, as well as Siglec-9 + MDSCs levels, while no correlation was observed between IL-6 levels and immune cell parameters.

Conclusion

MDSCs are increased in both ABI and CBI. Siglec-9 acts as an immune checkpoint on MDSCs in patients with ineffective treatment responses. Therefore, Siglec-9 represents a potential prognostic marker for Brucella infection. Ongoing research on prognostic markers of brucellosis is promising, and further clinical studies are warranted to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrucellosisMyeloid-Derived Suppressor CellsSialic Acid Binding Immunoglobulin-like LectinsImmune Checkpoint ProteinsHumansFemaleMaleAdultMiddle AgedBiomarkersCytokinesAnti-Bacterial AgentsProgrammed Cell Death 1 ReceptorHepatitis A Virus Cellular Receptor 2Young AdultInterleukin-6BrucellaChina

Stichwörter der Autor:innen

BrucellosisCytokinesMDSCsPD-1Siglec-9Tim-3

Substanzen

BiomarkersCytokinesAnti-Bacterial AgentsProgrammed Cell Death 1 ReceptorSialic Acid Binding Immunoglobulin-like LectinsPDCD1 protein, humanHepatitis A Virus Cellular Receptor 2Interleukin-6Immune Checkpoint ProteinsHAVCR2 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • School of Public Health, Xinjiang Medical University, Urumqi, China.
  • Department of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi, China.
  • Reproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shi, H., Qi, X., Shang, K., Tian, T., Ding, J., Li, M., Xu, R., Pu, F., Kuang, J., Zhu, Y., & Zhang, F. (2025). Siglec-9 acts as an immune checkpoint marker on MDSCs in brucella infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1652116

Vancouver

Shi H, Qi X, Shang K, Tian T, Ding J, Li M, et al. Siglec-9 acts as an immune checkpoint marker on MDSCs in brucella infection. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1652116

BibTeX
@article{Shi2025,
  author = {Shi, Huidong and Qi, Xinxin and Shang, Kaiyu and Tian, Tingting and Ding, Jianbing and Li, Mingzhe and Xu, Ruixue and Pu, Fuling and Kuang, Junyu and Zhu, Yuejie and Zhang, Fengbo},
  title = {Siglec-9 acts as an immune checkpoint marker on MDSCs in brucella infection},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1652116}
}
Kostenlos starten →